Skip to main content
Equibles
SGRY logo

SGRY · Surgery Partners, Inc. · Metrics

Track SGRY — free

Use SGRY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SGRY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$14.38 +0.26 (+1.84%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$1.88B
Shares
130.92M

SGRY metrics

72 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$14.38
Market cap
$1.88B

Price action

20 metrics
Price change (1W)
+0.8%
Price change (30D)
-4.3%
Price change (3M)
-6.1%
Price change (6M)
+16.2%
Price change (YTD)
-6.9%
Price change (1Y)
-35.0%
Trailing year
Price change (5Y)
-70.1%
52-week high
$22.94
52-week low
$11.49
Change from 52-week high
-37.3%
Change from 52-week low
+25.2%
Annualized volatility
48.2%
Annualized volatility (3M)
50.2%
Beta
0.7
RSI (14D)
49.1
Price vs SMA 50
-5.3%
Price vs SMA 200
-2.3%
Avg volume (3M)
1.91M
Relative volume
0.7
Average dollar volume
$28.65M

Company

3 metrics
Sector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
130.92M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.6×
reciprocal yield 178.8%
P / book
1.1
reciprocal yield 88.7%
FCF yield
10.0%
TTM · current market cap
Buyback yield
—
P / FCF
10.0
reciprocal yield 10.0%
P / operating cash flow
7.3
reciprocal yield 13.7%
Earnings yield
-4.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2.0×
reciprocal yield 50.4%
EV / revenue historical average (5Y)
2.3×
reciprocal yield 43.4%
EV / EBIT historical average (3Y)
17.1×
reciprocal yield 5.8%
EV / EBIT historical average (5Y)
18.6×
reciprocal yield 5.4%
EV / EBITDA historical average (3Y)
12.1×
reciprocal yield 8.2%
EV / EBITDA historical average (5Y)
13.5×
reciprocal yield 7.4%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-10

Profitability

9 metrics
Gross margin
—
Operating margin
11.4%
Trailing 12 months
Net margin
-2.6%
Gross profit (TTM)
—
Operating profit (TTM)
$383.80M
Net income (TTM)
−$88.60M
Trailing 12 months
Diluted EPS (TTM)
$-0.69
FCF margin
5.6%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$13.25

Growth

11 metrics
Revenue growth YoY
+2.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$3.37B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.5%
Year over year · more shares
Revenue CAGR (3Y)
+9.2%
Revenue CAGR (5Y)
+12.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+35.7%
FCF CAGR (5Y)
-0.8%

Quality

14 metrics
Return on equity
-5.3%
Return on assets
-1.1%
Debt / equity
—
Current ratio
1.9
EBITDA (TTM)
$561.00M
Free cash flow (TTM)
$187.60M
Quick ratio
1.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$216.70M
Total assets
$8.05B
Total debt
$3.74B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$258.00M
Capital expenditures (TTM)
$70.40M
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$10.00M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
190
13F filer change QoQ
+6
Institutional ownership
121.1%

Short interest

3 metrics
Short interest
9.9%
Latest settlement · 4.7 days to cover
Days to cover
4.7d
Short-squeeze score
60 / 100

Insider activity

2 metrics
Net insider buying (90D)
$161,212
Insider-sentiment score
79 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1638833 CUSIP 86881A100 13F (30d) 72 filings 72 filers Visit website Investor relations